Questions Answered in This Report:

    • Which therapies capture the maximum patient share in different lines of therapies? 
    • Which therapies are used alone and which ones are used in combination? 
    • What percentage of newly diagnosed patients on key SLE  therapies add or switch to new agents as they move through lines of treatment? 
    • What are the persistency and compliance rates for key SLE  therapies? 


Systemic Lupus Erythematosus ( SLE ) is an area of high unmet need with few effective therapies. Furthermore, the many distinct manifestations of the disease mean that treatment is highly heterogeneous depending on the specific organ systems and severity of the disease. This has made clinical trial design as well as understanding of the potential market for therapies in SLE a unique challenge. The approval of Benlysta in 2011 marked the first new drug to be launched for SLE in over 50 years, and a number of treatments in development seek approval for this condition. Meanwhile, a number of drugs including Rituxan are prescribed off-label to treat the condition. 
The Treatment Algorithms: Claims Data Analysis report examines physicians’ actual prescribing behavior as they initiate therapy and move through second– and third-line choices. Our analysis is supported by a deep longitudinal patient-level claims dataset and provides a representative sample of treatment practice for Medicare supplemental and commercially insured patients.

Related Reports

Systemic Lupus Erythematosus - Access & Reimbursement - Detailed, Expanded Analysis (US)

The systemic lupus erythematosus (SLE) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline’s Benlysta—which launched in 2011&...

View Details

Systemic Lupus Erythematosus - Current Treatment - Systemic Lupus Erythematosus | Treatment Algorithms: Claims Data Analysis | US | 2020 | Dashboard


View Details

Systemic Lupus Erythematosus - Landscape & Forecast - Disease Landscape & Forecast

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course,...

View Details

Systemic Lupus Erythematosus - Unmet Need - Detailed, Expanded Analysis: Moderate To Severe Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range o...

View Details